当前位置: X-MOL 学术Heart Vessels › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Effect of oral tolvaptan for 1 year in patients with functional mitral regurgitation
Heart and Vessels ( IF 1.5 ) Pub Date : 2021-09-02 , DOI: 10.1007/s00380-021-01934-8
Fukuko Nagura 1 , Akihisa Kataoka 1 , Ruri Ishibashi 1 , Miho Mitsui 1 , Hirofumi Hioki 1 , Masanari Kuwabara 2 , Kiyoko Uno 2 , Yusuke Watanabe 1 , Naoyuki Yokoyama 1 , Ken Kozuma 1
Affiliation  

The effect of the oral selective vasopressin V2-receptor antagonist tolvaptan for chronic phase therapy on patients with FMR remains unclear. We aimed to determine the efficacy of oral tolvaptan in patients with significant functional mitral regurgitation (FMR) to reduce the mortality and rehospitalization due to worsening heart failure (HF). We enrolled 219 patients (mean age 76 ± 9 years, 59.4% men) who were admitted at our hospital due to congestive HF during different two 1-year periods. The patients were divided into 2 groups: those who had significant FMR (MR ≥ grade 2 [n = 76]) and those who did not (MR < grade 2 [n = 143]) at discharge. The patients were further divided into a study group that received tolvaptan during follow-up and a control group that did not receive tolvaptan. We used an inverse probability of treatment weighting method with the primary end point defined as overall all-cause mortality and rehospitalization due to worsening HF within 1 year. Of the 76 patients with significant FMR at discharge, 2 of 20 (10%) who were administered tolvaptan died and 8 (40%) were readmitted to a hospital. Of the 56 patients who did not receive tolvaptan, 2 (3.5%) died and 18 (27.5%) required rehospitalization. After multiple adjustments, there were no significant differences for overall survival and rehospitalization between the groups (log-rank p = 0.700 and 0.510, respectively). Our results suggest that oral tolvaptan administration in addition to conventional diuretics had less impact on outcomes in patients with significant FMR.



中文翻译:

口服托伐普坦 1 年对功能性二尖瓣关闭不全患者的疗效

口服选择性加压素 V2 受体拮抗剂托伐普坦用于慢性期治疗 FMR 患者的效果仍不清楚。我们旨在确定口服托伐普坦对显着功能性二尖瓣关闭不全 (FMR) 患者降低因心力衰竭 (HF) 恶化而导致的死亡率和再住院率的疗效。我们招募了 219 名患者(平均年龄 76 ± 9 岁,男性占 59.4%),他们在不同的两个 1 年期间因充血性心衰入院。将患者分为 2 组:具有显着 FMR 的患者(MR ≥ 2 级 [ n  = 76])和没有显着 FMR 的患者(MR < 2 级 [ n = 143]) 出院时。患者进一步分为在随访期间接受托伐普坦的研究组和未接受托伐普坦的对照组。我们使用了逆向治疗概率加权法,主要终点定义为 1 年内因 HF 恶化而导致的总体全因死亡率和再住院率。在出院时有显着 FMR 的 76 名患者中,20 名接受托伐普坦治疗的患者中有 2 名(10%)死亡,8 名(40%)再次入院。在未接受托伐普坦治疗的 56 名患者中,2 人(3.5%)死亡,18 人(27.5%)需要再次住院治疗。经过多次调整后,各组之间的总生存率和再住院率无显着差异(log-rank p = 0.700 和 0.510,分别)。我们的研究结果表明,除了常规利尿剂外,口服托伐普坦对显着 FMR 患者的预后影响较小。

更新日期:2021-09-02
down
wechat
bug